Suh K - Search Results

1

Consensus Obtained for the Nephrotoxic Potential of 167 Drugs in Adult Critically Ill Patients Using a Modified Delphi Method.

Gray MP, Barreto EF, Schreier DJ, Kellum JA, Suh K, Kashani KB, Rule AD, Kane-Gill SL. Gray MP, et al. Among authors: suh k. Drug Saf. 2022 Apr;45(4):389-398. doi: 10.1007/s40264-022-01173-4. Epub 2022 Apr 7. Drug Saf. 2022. PMID: 35389144 Free PMC article.

2

A systematic review of cost-effectiveness analyses across the acute kidney injury landscape.

Suh K, Kellum JA, Kane-Gill SL. Suh K, et al. Expert Rev Pharmacoecon Outcomes Res. 2021 Aug;21(4):571-578. doi: 10.1080/14737167.2021.1882307. Epub 2021 Feb 7. Expert Rev Pharmacoecon Outcomes Res. 2021. PMID: 33522323

3

Trends in endpoint use in pivotal trials and efficacy for US Food and Drug Administration-approved solid tumor therapies, 1995-2021.

Alabaku O, Laffey TN, Suh K, Li M. Alabaku O, et al. Among authors: suh k. J Manag Care Spec Pharm. 2022 Nov;28(11):1219-1223. doi: 10.18553/jmcp.2022.28.11.1219. J Manag Care Spec Pharm. 2022. PMID: 36282934 Free PMC article. Review.

4

Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010-2019.

Zhu W, Tang X, Heyman RA, Cai T, Suh K, Seeger JD, Xia Z. Zhu W, et al. Among authors: suh k. Neurol Ther. 2022 Sep;11(3):1147-1165. doi: 10.1007/s40120-022-00358-4. Epub 2022 May 22. Neurol Ther. 2022. PMID: 35598225 Free PMC article.

5

Correction to: Cost Effectiveness of Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Patients with Knee Osteoarthritis.

Suh K, Cole BJ, Gomoll A, Lee SM, Choi H, Ha CW, Lim HC, Kim MK, Ha GY, Suh DC. Suh K, et al. Among authors: suh dc. Appl Health Econ Health Policy. 2023 Jan;21(1):153. doi: 10.1007/s40258-022-00768-3. Appl Health Econ Health Policy. 2023. PMID: 36269507 Free PMC article. No abstract available.

6

The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma.

Suh K, Carlson JJ, Xia F, Williamson T, Sullivan SD. Suh K, et al. J Manag Care Spec Pharm. 2022 Jun;28(6):622-630. doi: 10.18553/jmcp.2022.21373. Epub 2022 Apr 1. J Manag Care Spec Pharm. 2022. PMID: 35362337

Given the limitations of this analytic approach and the small sample size for larotrectinib in trials, future studies should reassess the comparative effectiveness of larotrectinib vs standard of care as treated patients accrue and long-term survival data mature. DISCLOSURES: …

Given the limitations of this analytic approach and the small sample size for larotrectinib in trials, future studies should reassess the co …

7

A Computational Framework to Characterize the Cancer Drug Induced Effect on Aging Using Transcriptomic Data.

Zhao Y, Wang Y, Yang D, Suh K, Zhang M. Zhao Y, et al. Among authors: suh k. Front Pharmacol. 2022 Jun 29;13:906429. doi: 10.3389/fphar.2022.906429. eCollection 2022. Front Pharmacol. 2022. PMID: 35847024 Free PMC article.

8

Exploring Medication Adherence with P2Y₁₂ Inhibitors Using Conditional and Unconditional Quantile Regression Approaches.

Suh K, Basu A, Carlson JJ, Branch KR. Suh K, et al. Am J Cardiovasc Drugs. 2021 Mar;21(2):193-204. doi: 10.1007/s40256-020-00405-1. Am J Cardiovasc Drugs. 2021. PMID: 32232734

9

International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility.

Jung JH, Kim DJ, Suh K, You J, Lee JH, Joung KI, Suh DC. Jung JH, et al. Among authors: suh dc, suh k. Int J Environ Res Public Health. 2021 Jan 14;18(2):670. doi: 10.3390/ijerph18020670. Int J Environ Res Public Health. 2021. PMID: 33466893 Free PMC article.

10

Cost Effectiveness of Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Patients with Knee Osteoarthritis.

Suh K, Cole BJ, Gomoll A, Lee SM, Choi H, Ha CW, Lim HC, Kim MK, Ha GY, Suh DC. Suh K, et al. Among authors: suh dc. Appl Health Econ Health Policy. 2023 Jan;21(1):141-152. doi: 10.1007/s40258-022-00762-9. Epub 2022 Sep 22. Appl Health Econ Health Policy. 2023. PMID: 36136263 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,543 results

Search Page